Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to Arms

Affiliations

• ¹ Covance, Princeton, NJ.
• ² East Suffolk and North Essex NHS Foundation Trust, Ipswich, United Kingdom.
• ³ Madrid Medical Doctors Association, Madrid, Spain.
• ⁴ Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, United Kingdom.
• ⁵ START Madrid-FJD, Hospital Fundación Jiménez Díaz, Madrid, Spain.
• ⁶ Hospital Universitario La Paz, IdiPAZ, Madrid, Spain.
• ⁷ Oncology Medicine Department, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
• ⁸ F Hoffmann-La Roche, Basel, Switzerland.
• ⁹ Salt Lake City Medical Centre, Kolkata, India.
• ¹⁰ Immunomedics, Morris Plains, NJ.
• ¹¹ R&D Oncology, AstraZeneca, Cambridge, United Kingdom.
• ¹² Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
• ¹³ University Hospital Fundacion Jimenez Diaz, Autonomous University of Madrid, Madrid, Spain.
• ¹⁴ Leeds Cancer Centre, Patient and Public Involvement Group, Leeds, United Kingdom.
• ¹⁵ Istituto Europeo di Oncologia, IRCCS, Milan, Italy.
• ¹⁶ University of Milano, Milan, Italy.
• ¹⁷ Apricity Health, Houston, TX.
• ¹⁸ Dell Medical School at the University of Texas at Austin, Austin, TX.
• ¹⁹ HistoGeneX, Antwerp, Belgium.
• ²⁰ Lytix Biopharma, Oslo, Norway.
• ²¹ IOB Institute of Oncology, Quiron Group, Madrid, Spain.
• ²² Canadian Cancer Trials Group, Queen's University, Kingston, Ontario, Canada.
• ²³ University of Leeds and Leeds Teaching Hospitals Trust, Leeds, United Kingdom.